Aims: Zonisamide is a new anti-epileptic drug whose mechanism of action is associated with neurotransmission systems also involved in the pathogenesis of addiction. Recently, the role of memory processes and the hippocampus (Hp) is underlined in dependence. In our previous study, we determined that zonisamide decreases changes in hippocampal bioelectric activity induced by a single dose of ethanol. Methods: This study uses a pharmaco-EEG method to examine the impact of zonisamide on the development and course of alcohol dependence in rabbits. Quantitative changes in EEG were observed in the midbrain reticular formation, Hp and frontal cortex. Zonisamide was administered p.o. once a day at dose of 30 mg/kg/day during the entire experiment. Solutions with increasing concentrations of ethanol were administered for 6 weeks, followed by a 2-week period of abstinence. Results: The long-term administration of ethanol caused characteristic changes in rabbit EEG recordings, which were associated with a shift toward lower frequencies resulting in a depressive effect on the bioelectric activity of selected brain structures. Co-administration of zonisamide and ethanol caused a reduction of ethanol-induced alterations. Changes in EEG recordings were different during period of abstinence and were associated with potent shift toward the high frequencies. Zonisamide significantly decreased encephalographic features of neuronal hyperactivity when administered during the abstinence. Conclusion: Zonisamide decreases ethanol-and abstinence-induced changes in the EEG recordings. These effects may be a significant part of drug's mechanism of action in alcohol addiction therapy. Short Summary: A pharmaco-EEG method was used to determine the influence of a new antiepileptic drug zonisamide on the development and course of alcohol dependence in rabbits. The drug co-administered with ethanol decreased alcohol-induced changes in selected brain structures. Zonisamide also decreases abstinence-induced changes in the EEG recordings.
INTRODUCTION
Several drugs have been approved by the Food and Drug Administration for the treatment of alcohol use disorder (AUD), but they have limitations, their efficacy is low and they are influenced by many factors. It has been demonstrated that acamprosate prevents relapse in addicts motivated by 'negative reinforcement' while naltrexone is effective in individuals with 'positive reinforcement' (Ooteman et al., 2009) . Combined acamprosate and naltrexone reduced relapse rates in patients with alcoholism comparing to acamprosate-but not naltrexone-treated group. Furthermore, patients treated with combined medications demonstrated a tendency for a better outcome regarding time to first drink and time to relapse (Kiefer et al., 2003) . On the other hand, SSRIs provide benefit in terms of drinking outcome in subjects with depression (Moak et al., 2003) .
Therefore, attention has recently been drawn to the new generation of anti-epileptic drugs (AEDs), whose multidirectional mechanism of action involves the modulating effects of various neurotransmitter systems. As these are known to be involved in the pathogenesis of alcohol addiction (Franck and Jayaram-Lindström, 2013) , the drugs have been included in experimental studies based on dependence (Cagetti et al., 2004; Knapp et al., 2007; Nguyen et al., 2007; Pietrzak et al., 2014; Zwierzyń ska et al., 2016) and in clinical trials. So far, the most promising results have been demonstrated by topiramate, which was found to reduce the number of drinking days and amount of consumed alcohol in addicted patients (Johnson et al., 2003; Johnson et al., 2007) . Gabapentin, another drug from this group, extended the duration of abstinence and reduced the amount of alcohol consumed in subjects demonstrating addiction (Furieri and Nakamura-Palacios, 2007; Mason et al., 2014) . However despite this research, it has not been possible to determine the key elements of the 'anti-alcoholic' action of these drugs.
One AED is zonisamide, which acts by modulating voltagedepend Na + channels and inhibits low-threshold T-type Ca 2+ channels preventing the formation of action potential (Perez-Reyes, 2003; Biton, 2007) . In addition, the drug influences the synthesis, release and distribution of many neurotransmitters involved in the pathogenesis of addiction, such as glutamate, GABA, dopamine, serotonin and acetylcholine (Okada et al., 1992; Kawai et al., 1994; Biton, 2007) . Experimental studies have also demonstrated the neuroprotective effect of zonisamide (Topcu et al., 2014; Sano et al., 2015) . Few experiments have so far assessed the effect of zonisamide on alcohol intake in rats and mice (Knapp et al., 2007) . It has been shown that the drug successfully reduced the amount of ethanol consumption in animals. Previous pharmaco-EEG studies have found that when applied in multiple doses, zonisamide reduces the bioelectric changes induced by acute dose of ethanol in the EEG of the hippocampus (Hp), the structure associated with the consolidation of memory (Pietrzak et al., 2014) . This effect could be related to the influence of zonisamide on memory processes, which have recently been found to play a significant role in the development of addiction, and this property could be part of the 'anti-alcoholic' action of the drug.
Following on from these findings, the present study examines the impact of zonisamide on changes in rabbit EEG during long-term administration of ethanol leading to the development of addiction as well as following abstinence period.
MATERIALS AND METHODS

Animals and treatment
Twenty-one rabbits (males and females) weighing 4.5-5.5 kg were used in the study. The rabbits were housed in individual cages under normal laboratory conditions (20-22°C, 12 h light/12 h of dark cycle) with free access to commercial chow (LSK; Agropol, Poland). Eleven animals were used in the experimental group and 10 animals in the ethanol group. They were provided free access only to a solution of ethanol that was given in increasing concentrations (ethanol: sucrose 1st week 10%:10%, 2nd week 15%:7%, 3rd-4th weeks 17%:5%, 4-6th weeks 19%:0% 
EEG procedure
Monopolar electrodes were implanted into the following structures in the rabbit brain: the midbrain reticular formation (MRF; P 8 mm, L 3 mm, H 15 mm); the Hp (P 3 mm, L 5 mm, H 5 mm) and the frontal cortex (FC ;A 3 mm, L 2 mm), according to Sawyer et al., 1954 . The implantation was performed under butorphanol (0.1 mg/kg), ketamine (10 mg/kg) and xylazine (0.5 mg/kg) anaesthesia. The cortical electrodes were made of 0.15 mm diameter silver wire with a ball at the tip. The subcortical electrodes were made of 0.11 mm diameter Teflon-covered steel wire (Leico Indus-tries, New York). At the end of the experiment, the positions of the electrode tips were verified histologically.
The first pharmaco-EEG recordings were performed 4 weeks after surgery but before the alcohol administration period (initial value). Then EEG traces were recorded after each week of the study. EEG recordings were taken with an eight-channel electroencephalograph (Medicor-EEG 8 S, Hungary) with the time constant set at 0.3 s and the high filter set at 60 Hz. During the recordings, the animals remained in a cage with a transparent roof and front. The cage was located in a quiet room, and camera recorded their behaviour. One-minute artefact-free EEG recordings selected by the experimenter were taken for computer analysis. EEG samples were digitized at the rate of 128 samples/s, and the Fourier transformation was calculated of consecutive 4 s epochs for each channel. Each spectrum consisted of 512 terms for a frequency range between 0 and 45 Hz, with each term having a width of 0.25 Hz. For further statistical analysis, the transformed data was compressed into the six frequency bands: 0.5-4 Hz (delta rhythm), 4-7 Hz (theta rhythm), 7-10 Hz (slow-alpha rhythm), 10-13 Hz (fast-alpha rhythm), 13-30 Hz (slow-beta rhythm) and 30-45 Hz (fast-beta rhythm).
Analysis of results
The results are presented as a percentage change of the initial value. The normality of the distribution was checked by the KolmogorovSmirnov test, with Lilliefors correction. Statistical analysis was performed with the Kruskal-Wallis (ANOVA) test and the MannWhitney U-test (comparison between groups), or the Wilcoxon matched pair test (comparison within groups), using Statistica v.10 software. A P-value of 0.05 or less was considered to indicate a statistically significant difference for all statistical tests.
RESULTS
Due to the fact that the forced ethanol model was used, no significant differences were found between groups with regard to alcohol consumption. The ethanol consumption rate was 2.12 ± 0.23 g/kg/ day in the ethanol group and 2.39 ± 0.29 g/kg/day in experimental group.
The mean contribution of particular frequencies to total power spectrum (histogram) in the rabbits has been presented in the Table 1 . Bioelectric activity changes were noted in all studied brain structures after 2 weeks of ethanol administration: the MRF, Hp and FC (Fig. 1A) . In the recording from the MRF, the changes were most pronounced in the 4-13 Hz range. An increase in the 13-30 Hz band was observed in the Hp and in the 4-7 Hz band in the FC.
After 4 weeks of alcohol administration, ethanol-induced changes were also noted in all studied brain structures. The most pronounced changes were observed in the Hp, where the significant increase in low frequency (0.5-4 Hz) and decreases in the 10-13 and 30-45 Hz bands were noted (Fig. 1B) . In the MRF recordings, a significant increase was reported in the 4-10 Hz range. Finally, a decrease of low frequency (0.5-4 Hz) was noted in the FC.
After 6 weeks of ethanol administration, in the MRF, an increase in the 4-10 Hz range was observed, as in previous weeks, and a decrease in the 30-45 Hz band was noted (Fig. 1C) . Furthermore, decreases in the 10-13 and 30-45 Hz bands were still observed in the Hp. Moreover, the 4-7 Hz band increased while the 10-45 Hz bands decreased in the FC.
In the second stage of the study, pharmaco-EEG examination was carried out in the tested rabbits following 1 week of abstinence. The changes in the EEG recordings included all studied brain structures ( Fig. 2A) . In the MRF, a significant increase remained in the 4-10 Hz bands while the decrease in low frequency (0.5-4 Hz) were noted. In the Hp, the 10-13 Hz band decreased while the high frequency (30-45 Hz) increased. Finally, in the recording from the FC, significant decreases in the 0.5-4 and 10-13 Hz bands were reported and an increase in the 4-7 Hz band was observed.
After 2 weeks of abstinence, the most pronounced changes were observed in the MRF and Hp (Fig. 2B ). In the recordings from the MRF, a decrease was only observed in the low frequency band (0.5-4 Hz) while significant increases were seen in other bands (4-45 Hz). Moreover, significant increases were also noted in the high bands (13-45 Hz) and a decrease in 0.5-4 Hz in the Hp. Changes in the FC were not statistically significant.
After 2-week co-administration of zonisamide and ethanol, significant changes in the EEG recordings were noted in all studied brain structures (Fig. 3A) . In the MRF, zonisamide reduced ethanolinduced changes in the 4-10 and 13-30 Hz bands. A significant decrease in the 7-45 Hz range was observed in the Hp compared to ethanol group. Changes were also noted compared with the initial values, including an increase in 0.5-4 Hz and decrease in 13-45 Hz. Finally, in the FC, zonisamide reduced ethanol-induced changes in the 4-10 Hz range and also increased the low frequency (0.5-4 Hz). A significant increase was also noted in 0.5-4 Hz compared to initial values.
After 4 weeks of zonisamide and ethanol co-administration, the low frequency band (0.5-4 Hz) increased and high frequency (30-45 Hz) decreased in the MRF compared to the initial values (Fig. 3B) . A reduction of ethanol-induced changes in all bands without 10-13 Hz was demonstrated in the EEG spectrum from the MRF compared to the ethanol group. In the Hp, a significant Table 1 . Mean share of particular frequencies in total power spectrum (%) ± SD n = 21 decrease was observed in the 0.5-7 Hz and 10-13 Hz frequency bands compared to ethanol group. Furthermore, the high frequency band (30-45 Hz) decreased compared to the initial value. In the recording from FC, a significant increase in low frequency (0.5-4 Hz) and a reduction in the 4-10 Hz bands were observed in comparison with those of the ethanol group and baseline values. The drug decreased also ethanol-induced changes in the 13-30 Hz band. After 6 weeks of ethanol and zonisamide co-administration, significant changes were still observed in the low frequencies in the recordings from the MRF (Fig. 3C) . Zonisamide reduced the ethanol-induced changes in the 4-7 Hz band. Compared to both initial values and ethanol group, the drug decreased the proportion of the 7-10 Hz frequency band but increased 0.5-4 Hz. A significant decrease was observed in the 10-45 Hz frequency range from the Hp. In the FC recordings, the drug increased the proportion of 0.5-4 and 10-45 Hz frequency range in comparison with ethanol group. The 4-10 Hz frequency range was still decreased compared to the ethanol group and initial values. Moreover, an increase in 0.5-4 Hz band was also observed compared to initial values.
After 1 week of abstinence, pronounced effects were observed in all studied brain structures in rabbits, which were still receiving zonisamide (Fig. 4A) . In the MRF, the drug increased the proportion of the 0.5-4 Hz band and decreased 4-10 Hz compared to abstinence-induced changes. In comparison with initial values, zonisamide increased changes in 0.5-4 and 10-13 Hz while a decrease in 30-45 Hz was observed. In the Hp, significant changes were noted only compared to the abstinence group. The drug increased the proportion of the 10-13 Hz band and reduced the 13-45 Hz bands. Finally in the FC, zonisamide potentiated changes in 0.5-4 Hz and decreased the 4-7 Hz band in comparison with both initial and abstinence-induced values. Moreover, an increase in the 10-13 Hz band was observed in comparison to abstinence group. However, the reduction in the 7-10 Hz frequency band was noted compared to baseline values.
After 2 weeks of abstinence in the recording from MRF, zonisamide increased the low frequency band (0.5-4 Hz) while an overall reduction of the 4-45 Hz range was observed compared to abstinenceinduced changes (Fig. 4B) . Furthermore in this brain structure, the drug increased the low-frequency band (0.5-4 Hz) and decreased the proportion of the 7-10 Hz and 30-45 Hz bands compared with their initial values. As in the previous week, the Hp only 
DISCUSSION
The pharmaco-EEG method was used to assess the effect of longterm co-administration of zonisamide and ethanol on the bioelectric activity of rabbit brains. It enables an assessment of the central effect of substances and the interaction between them based on the analysis of quantitative changes in the EEG spectrum of selected brain structures (Cao et al., 2014) .
The long-term administration of ethanol caused characteristic changes in rabbit EEG recordings, which were pronounced in all studied brain structures after 2 weeks of administration. These changes were mainly associated with a shift towards lower frequencies. In the following weeks of ethanol administration, changes had similar nature and involved the entire EEG spectrum after 6 weeks. During this stage, a reduction in the proportion of high frequencies was also observed.
In animals, which received zonisamide with alcohol, a reduction of ethanol-induced changes was observed in the studied brain structures. After 2 weeks, these changes were especially pronounced in the recordings from the MRF and Hp. However, after 4 and 6 weeks, they were also expressed in the recordings from the FC. The changes observed after 6 weeks were associated with an increase in the proportion of delta rhythm and a reduction of theta and slowalpha rhythms from the MRF and Hp. Finally in the FC recordings, the changes included the entire spectrum.
The results from a few experimental studies performed in animal models of dependence indicated that zonisamide given at a dose of 50 mg/kg reduced the ethanol intake in rodents (Knapp et al., 2007) . In our previous pharmaco-EEG study (Pietrzak et al., 2014) , we evaluated the effect of zonisamide on ethanol-induced changes as a response to the administration a single high dose of ethanol. Zonisamide administered alone as a single high dose caused an increased proportion of delta rhythms in the Hp whereas the proportion of others frequencies decreased. Changes in EEG recordings after repeated administration of zonisamide were different and the shift of the spectrum toward fast rhythms was observed in all studied structures. Moreover, the multiple administration of the drug significantly reduced the sensitivity of the Hp to an acute dose of ethanol (Pietrzak et al., 2014) .
The results of clinical trials indicate that zonisamide given as a single dose of 100 mg reduced the quantity of ethanol selfadministration by risky drinkers in the second hour of its administration (Sarid-Segal et al., 2009) . Moreover in another clinical trial, the drug was well tolerated by patients presenting alcohol dependence and seems to have a positive effect on craving and total amount of drinks per day (Rubio et al., 2010a) . Other clinical studies have evaluated the effect of multiple zonisamide administration on alcohol consumption, level of alcohol craving in addicts and the safety of its use. When administered at doses of 300-400 mg/day for 12 weeks, the drug reduced the ethanol consumption and craving (Arias et al., 2010) , was well tolerated and did not affect the verbal fluency or psychomotor activity of patients (Knapp et al., 2010) . However, recent reports indicate that zonisamide can cause modest reduction in verbal fluency and working memory (Knapp et al., 2015) .
Observation of quantitative changes in EEG in rabbits, which had previously received ethanol, was carried out for 2 weeks of abstinence. During this period, changes were different in character and were associated with potent shift toward the high frequencies. These changes were most pronounced after 2 week of abstinence in the MRF and Hp. They reflect the state of neuronal hyperactivity characteristic for the abstinence and determine the severity of symptoms.
Zonisamide significantly reduced encephalographic features of neuronal hyperactivity when administered during the abstinence period. This was particularly noticeable in the recordings from the Hp and MRF, where the impact was observed across almost all the frequency range, which may be an important element of the beneficial effects of zonisamide on withdrawal symptoms. Currently, no similar data are present in the literature concerning this effect. However, a previous pharmaco-EEG study found retigabine, another antiepileptic drug, also reduced ethanol-induced changes and decreased changes caused by abstinence (Zwierzyń ska et al., 2016) . Promising results were obtained in a clinical trial, which compared the efficacy of zonisamide in the treatment of alcohol abstinence in addicts with that of diazepam, currently the first-choice drug. It was found that after 2 weeks administration, zonisamide decreased alcohol craving and symptoms of depression to the same degree as diazepam. After 3 weeks of treatment, the results obtained in patients receiving zonisamide were more favourable than those treated with diazepam (Rubio et al., 2010b) . The mechanism behind this beneficial protective added effect of some of the new generation of anti-epileptic drugs such as zonisamide has not been fully elucidated. An important element of this activity seems to be the effect of the drug on the function of the Hp, a structure associated with memory processes.
Recently, the importance of memory process in the development of addiction has been emphasized. Addiction and memory, forms of neuronal plasticity and adaptive changes leading to addiction, include the same cellular mechanisms that are involved in learning and memory (Nestler, 2013) . Chronic activation in neuronal systems by addictive substances may cause adaptive changes affecting a number of synaptic transmissions, receptors for neurotransmitters and changes in the structure and volume of the Hp. The results of several studies suggest that the Hp plays an important role in the mechanism of positive reinforcement, which consolidates the reaction and increases the probability of recurrence to encounter a specific stimulus. It seems that the Hp tonically inhibits the reward system (Zimmermann et al., 1997) . The impairment in the functioning of the Hp disrupts the formation of the correct memory trace connected with the negative phase of psychoactive substance reaction. Hence, appetitive behaviour predominates as a result of the action of the memory of the positive sensations associated with the substance. Craving and compulsive seeking are closely associated with the memory of their reward reaction in those addicted to psychoactive substances (Robinson and Berridge, 1993) .
The reduction of neuronal hyperactivity observed in the study could result from the neuroprotective activity of zonisamide, particularly in the Hp. It has been demonstrated that zonisamide affected hyperoxia-induced apoptosis in the developing rats brain and reduced the number of damaged neurons (Topcu et al., 2014) . In addition, the results from the study on the genetic mouse model of Parkinson's disease indicated that long-term administration of zonisamide can effectively reduce the loss of neurons within the nigrostriatal dopamine pathway (Sano et al., 2015) .
In summary, co-administration of zonisamide and ethanol reduced the ethanol-induced changes in the EEG spectrum. The beneficial effect of the drug was most clearly expressed in the withdrawal period when zonisamide reduced the neuronal hyperactivity characteristic for abstinence in all studied structures, especially in the Hp. This observation may indicate the existence of an important element of the beneficial effects of AEDs including zonisamide on the level of alcohol consumption in animal models of addiction and risky drinking people. Effects on memory can slow down or even inhibit the development of addiction, which may suggest a new direction for improving the effectiveness of AUD therapy.
